vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -12.9%, a 24.0% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -0.4%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-680.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 22.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
ANIP vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $340.0M |
| Net Profit | $27.5M | $-13.9M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | -17.2% |
| Net Margin | 11.1% | -12.9% |
| Revenue YoY | 29.6% | -0.4% |
| Net Profit YoY | 367.5% | -131.0% |
| EPS (diluted) | $1.14 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $340.0M | ||
| Q3 25 | $227.8M | $337.7M | ||
| Q2 25 | $211.4M | $319.2M | ||
| Q1 25 | $197.1M | $237.4M | ||
| Q4 24 | $190.6M | $341.5M | ||
| Q3 24 | $148.3M | $292.3M | ||
| Q2 24 | $138.0M | $270.7M | ||
| Q1 24 | $137.4M | $228.1M |
| Q4 25 | $27.5M | $-13.9M | ||
| Q3 25 | $26.6M | $33.5M | ||
| Q2 25 | $8.5M | $34.0M | ||
| Q1 25 | $15.7M | $2.8M | ||
| Q4 24 | $-10.3M | $44.8M | ||
| Q3 24 | $-24.2M | $28.8M | ||
| Q2 24 | $-2.3M | $22.7M | ||
| Q1 24 | $18.2M | $11.9M |
| Q4 25 | 14.1% | -17.2% | ||
| Q3 25 | 15.9% | 13.6% | ||
| Q2 25 | 6.6% | 14.5% | ||
| Q1 25 | 13.3% | 2.2% | ||
| Q4 24 | -2.3% | 15.3% | ||
| Q3 24 | -13.8% | 12.8% | ||
| Q2 24 | 3.7% | 10.4% | ||
| Q1 24 | 14.8% | 6.0% |
| Q4 25 | 11.1% | -12.9% | ||
| Q3 25 | 11.7% | 9.9% | ||
| Q2 25 | 4.0% | 10.6% | ||
| Q1 25 | 8.0% | 1.2% | ||
| Q4 24 | -5.4% | 13.1% | ||
| Q3 24 | -16.3% | 9.9% | ||
| Q2 24 | -1.7% | 8.4% | ||
| Q1 24 | 13.2% | 5.2% |
| Q4 25 | $1.14 | $-0.41 | ||
| Q3 25 | $1.13 | $0.98 | ||
| Q2 25 | $0.36 | $0.99 | ||
| Q1 25 | $0.69 | $0.08 | ||
| Q4 24 | $-0.45 | $1.32 | ||
| Q3 24 | $-1.27 | $0.85 | ||
| Q2 24 | $-0.14 | $0.67 | ||
| Q1 24 | $0.82 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $299.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $1.7B |
| Total Assets | $1.4B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $299.3M | ||
| Q3 25 | $262.6M | $274.8M | ||
| Q2 25 | $217.8M | $233.7M | ||
| Q1 25 | $149.8M | $181.0M | ||
| Q4 24 | $144.9M | $279.3M | ||
| Q3 24 | $145.0M | $179.8M | ||
| Q2 24 | $240.1M | $208.1M | ||
| Q1 24 | $228.6M | $216.5M |
| Q4 25 | $540.7M | $1.7B | ||
| Q3 25 | $505.8M | $1.8B | ||
| Q2 25 | $436.8M | $1.8B | ||
| Q1 25 | $418.6M | $1.7B | ||
| Q4 24 | $403.7M | $1.7B | ||
| Q3 24 | $405.9M | $1.7B | ||
| Q2 24 | $455.8M | $1.7B | ||
| Q1 24 | $452.0M | $1.7B |
| Q4 25 | $1.4B | $5.1B | ||
| Q3 25 | $1.4B | $5.8B | ||
| Q2 25 | $1.3B | $4.7B | ||
| Q1 25 | $1.3B | $4.5B | ||
| Q4 24 | $1.3B | $4.4B | ||
| Q3 24 | $1.3B | $4.6B | ||
| Q2 24 | $920.8M | $4.2B | ||
| Q1 24 | $914.5M | $3.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $-664.3M |
| Free Cash FlowOCF − Capex | $29.1M | $-680.1M |
| FCF MarginFCF / Revenue | 11.8% | -200.0% |
| Capex IntensityCapex / Revenue | 0.5% | 4.6% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $-664.3M | ||
| Q3 25 | $44.1M | $-948.1M | ||
| Q2 25 | $75.8M | $-238.5M | ||
| Q1 25 | $35.0M | $-281.1M | ||
| Q4 24 | $15.9M | $129.4M | ||
| Q3 24 | $12.5M | $-202.0M | ||
| Q2 24 | $17.4M | $-237.8M | ||
| Q1 24 | $18.3M | $38.4M |
| Q4 25 | $29.1M | $-680.1M | ||
| Q3 25 | $38.0M | $-950.4M | ||
| Q2 25 | $71.8M | $-241.0M | ||
| Q1 25 | $32.5M | $-284.7M | ||
| Q4 24 | $13.5M | $116.4M | ||
| Q3 24 | $7.7M | $-204.0M | ||
| Q2 24 | $13.0M | $-241.7M | ||
| Q1 24 | $13.7M | $35.2M |
| Q4 25 | 11.8% | -200.0% | ||
| Q3 25 | 16.7% | -281.5% | ||
| Q2 25 | 34.0% | -75.5% | ||
| Q1 25 | 16.5% | -120.0% | ||
| Q4 24 | 7.1% | 34.1% | ||
| Q3 24 | 5.2% | -69.8% | ||
| Q2 24 | 9.4% | -89.3% | ||
| Q1 24 | 10.0% | 15.4% |
| Q4 25 | 0.5% | 4.6% | ||
| Q3 25 | 2.7% | 0.7% | ||
| Q2 25 | 1.9% | 0.8% | ||
| Q1 25 | 1.3% | 1.5% | ||
| Q4 24 | 1.3% | 3.8% | ||
| Q3 24 | 3.2% | 0.7% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 3.3% | 1.4% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | -28.34× | ||
| Q2 25 | 8.87× | -7.02× | ||
| Q1 25 | 2.23× | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | — | -7.01× | ||
| Q2 24 | — | -10.49× | ||
| Q1 24 | 1.00× | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
WD
Segment breakdown not available.
